Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.5 SEK | +0.91% | +2.40% | -8.96% |
Apr. 25 | Swedencare AB Approves Dividend for the Year 2023, Payable on May 3, 2024 | CI |
Apr. 25 | Transcript : Swedencare AB, Q1 2024 Earnings Call, Apr 25, 2024 |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.32 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.66 times its current sales, is high.
- The company is not the most generous with respect to shareholders' compensation.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.96% | 805M | D+ | ||
-14.40% | 76.62B | B+ | ||
+14.06% | 8.4B | B- | ||
+25.88% | 3.76B | B- | ||
+18.24% | 1.65B | - | ||
-8.82% | 1.53B | B | ||
-22.51% | 1.3B | C- | ||
-3.32% | 1.25B | - | ||
-10.11% | 1.19B | - | ||
+4.27% | 1.1B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SECARE Stock
- Ratings Swedencare AB